NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Intellia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$11.58+0.16 (+1.40%)
Close on Oct 19, 2026
- Market cap
- $1.55B
- P/E (TTM)
- –
- Dividend yield
- –
Intellia Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.62B | $164.85M |
| Enterprise Value | $1.18B | $87.06M |
| PS Ratio | 27.27 | 3.60 |
| PB Ratio | 2.23 | 2.03 |
| P/TBV Ratio | 2.23 | 2.31 |
Enterprise value
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 19.91 | 2.43 |
Income (trailing twelve months)
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Revenue | $59.51M | $57.94M |
| Operating Income | -$423.48M | -$21.44M |
| Net Income | -$399.98M | -$22.46M |
| EBITDA | -$414.40M | -$16.91M |
| EPS (Diluted) | -$3.36 | -$0.83 |
Margins
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -711.7% | -44.5% |
| Profit Margin | -672.2% | -39.2% |
| EBITDA Margin | -696.4% | -31.3% |
| FCF Margin | -586.0% | -8.85% |
Returns
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -6424.8% | -53.1% |
| Return on Assets (ROA) | -45.6% | -41.0% |
| Return on Capital Employed (ROCE) | -54.4% | -37.8% |
Growth
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 12.6% | 6.01% |
| Revenue Growth (3Y CAGR) | 9.09% | 2.25% |
| Revenue Growth (5Y CAGR) | 3.13% | 6.42% |
Balance sheet
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $437.76M | $62.42M |
| Net Cash (Debt) | $437.76M | $15.68M |
| Net Cash Per Share | $3.12 | $0.66 |
| Equity (Book Value) | $727.71M | $48.79M |
| Book Value Per Share | $5.19 | $1.36 |
| Tangible Book Value | $727.71M | $23.06M |
| Working Capital | $448.44M | $75.77M |
Financial position
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.65 | 3.30 |
| Quick Ratio | 5.61 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$346.64M | -$12.35M |
| Capital Expenditures | -$2.04M | -$1.06M |
| Free Cash Flow | -$348.69M | -$20.28M |
| FCF Per Share | -$2.49 | -$0.42 |
Efficiency
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.07 | 0.38 |
| Revenue Per Employee | $157.84K | $398.96K |
| Profits Per Employee | -$1.06M | -$703.34K |
| Employee Count | 377 | 74 |
Dividends and yields
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -24.6% | -22.7% |
| FCF Yield | -21.5% | -9.07% |
Shares
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 140,127,000 | 58,179,650 |
| Shares Change (YoY) | 16.6% | 11.1% |
| Shares Change (QoQ) | 16.2% | 0.54% |
| Float | 137,510,000 | 49,173,100 |
| Shares Held by Insiders | 1.87% | 11.6% |
| Shares Held by Institutions | 102.8% | 59.4% |
Scores
| Measure | Intellia Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.03 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Intellia Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.